摘要
目的 探讨C-MYC和硫氧还蛋白相互作用蛋白(TXNIP)在前列腺癌和良性前列腺增生组织的表达及意义。方法 收集50例前列腺癌和49例良性前列腺增生组织,采用免疫组织化学技术检测C-MYC和TXNIP的表达,分析C-MYC和TXNIP的表达与临床资料的关系。结果 C-MYC在前列腺癌组织的阳性率为64.0%(32/50),良性前列腺增生组织为10.2%(5/49),差异有统计学意义(P<0.05)。TXNIP在前列腺癌组织的阳性率为36.0%(18/50),良性前列腺增生组织为79.6%(39/49),差异有统计学意义(P<0.05)。C-MYC和TXNIP的阳性表达率与前列腺特异性抗原(P<0.05)、TNM分期(P<0.05)显著相关。在Gleason评分<7分和>7分组,C-MYC的阳性表达差异有统计学意义(P<0.05),而<7分组和=7分组、=7分组和>7分组比较差异无统计学意义。在Gleason评分<7分和>7分组、<7分和=7分组,TXNIP的阳性表达差异有统计学意义(P<0.05),而在=7分和>7分组比较差异无统计学意义。前列腺癌中C-MYC与TXNIP的阳性表达呈负相关(r=-0.306,P<0.05)。结论 C-MYC和TXNIP与前列腺癌的发生发展、恶性程度密切相关。
Objective To study the expression and significance of C-MYC and thioredoxin-interacting protein (TXNIP) in prostate cancer and benign prostatic hyperplasia.Methods 50 cases of prostate cancer tissues and 49 cases of benign prostatic hyperplasia tissues were selected. The immunohistochemistry method was used to detect the expression level of C-MYC and TXNIP, and the correlation with clinical data.Results The positive rate of C-MYC in prostate cancer tissues was 64.0% (32/50) while in benign prostatic hyperplasia tissues was 10.2% (5/49, P<0.05). The positive rate of TXNIP in prostate cancer tissues was 36.0% (18/50) while in benign prostatic hyperplasia tissues was 79.6% (39/49, P<0.05). The differences were statistically significant. In prostate cancer tissues, the positive rate of C-MYC and TXNIP was significantly associated with the prostate specific antigen (P<0.05) and the TNM stage (P<0.05). In the Gleason score <7 and >7 group, the positive rate of C-MYC was statistically significant (P<0.05), while there was no statistical difference in the <7 and=7 group, =7 and >7 group. In the Gleason score <7 and >7 group, <7 and=7 group, the positive rate of TXNIP was statistically significant (P<0.05), while there was no statistical difference in=7 and >7 group. Overexpression of C-MYC was associated with downregulation of TXNIP (Spearman’s r=-0.306, P<0.05).Conclusion Overexpression of C-MYC and downregulation of TXNIP might be involved in the pathogenesis, development and degree of malignancy of prostate cancer. TXNIP is expected to be a potential therapeutic target for prostate cancer.
作者
谢鸣
高磊
潘铁军
Xie Ming;Gao Lei;Pan Tiejun(Department of Urology, Wuhan Clinical Medical College of Southern Medical University, Central Theater Command general hospital of the Chinese People's Liberation Army, Wuhan 430070, China)
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2019年第2期340-342,共3页
Chinese Journal of Experimental Surgery
基金
国家自然科学基金 (81502210).
